Sidley represented Immunovant, Inc., a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, in its US$550 million underwritten offering of 26,200,000 shares of its common stock at an offering price of US$21 per share. The transaction closed on December 12, 2025. Leerink Partners acted as the sole underwriter for the offering.
The Sidley team was led by Frank Rahmani and Istvan Hajdu (Capital Markets, Emerging Companies and Venture Capital), and included Carlton Fleming, Katie Klaben, and Jen Greenberg (Capital Markets); Emily Chazen (M&A); Torrey Cope and Kevin Sforza (Food, Drug and Medical Device); Dan Altman and Alvin Wang (Tax); Matt Dolan (Securities and Shareholder); Corey Perry (Employee Benefits and Executive Compensation); and Asher Rubin and Adriana Tibbits (Technology and Life Sciences Transactions).
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.